SANCUSO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, Tunisia, UK.

Active ingredients

The drug SANCUSO contains one active pharmaceutical ingredient (API):

1	Granisetron UNII WZG3J2MCOL - GRANISETRON
	Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5HT3 receptors). Pharmacological studies have demonstrated that granisetron is effective against nausea and vomiting as a result of cytostatic therapy.
	Read more about Granisetron

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SANCUSO Transdermal patch	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A04AA02	Granisetron	A Alimentary tract and metabolism → A04 Antiemetics and antinauseants → A04A Antiemetics and antinauseants → A04AA Serotonin (5HT3) antagonists
Discover more medicines within A04AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1567492
FI	Lääkealan turvallisuus- ja kehittämiskeskus	437941
FR	Base de données publique des médicaments	66912839
GB	Medicines & Healthcare Products Regulatory Agency	231507
HK	Department of Health Drug Office	61829
IT	Agenzia del Farmaco	042924011
LT	Valstybinė vaistų kontrolės tarnyba	1066216
NL	Z-Index G-Standaard, PRK	105589
PL	Rejestru Produktów Leczniczych	100316438
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69033001
SG	Health Sciences Authority	14391P
TN	Direction de la Pharmacie et du Médicament	15083011
US	FDA, National Drug Code	42747-726